Video

Dr. Simon on the Evaluation of Datopotamab Deruxtecan in TROP-2–Expressing Solid Tumors

George Simon, MD, FACP, FCCP, discusses the evaluation of datopotamab deruxtecan in TROP-2–overexpressing solid tumors.

George Simon, MD, FACP, FCCP, chair, Department of Medical Oncology, Advent Health, department chair, Medical Oncology, Moffit Cancer Center, discusses the evaluation of datopotamab deruxtecan (DS-1062) in TROP-2–overexpressing solid tumors.

The phase 1 TROPION-PanTumor01 trial (NCT03401385) evaluated the safety and tolerability of the TROP-2–targeting antibody-drug conjugate (ADC), datopotamab deruxtecan.

The goal of the study was to understand how TROP-2–overexpressing solid tumors reacted to datopotamab deruxtecan, Simon adds. 

The trial served as a preliminary step before ADC is evaluated in combination with other therapies and against the current standard of care, Simon continues. The phase 1 study will inform a more detailed portfolio of studies that will come down the line, Simon concludes.

Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive(R).

Related Videos
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Thomas Westbrook, MD
Massimo Cristofanilli, MD, attending physician, NewYork-Presbyterian Hospital; professor, medicine, Weill Cornell Medical College, Cornell University
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Ajay K. Nooka, MD, MPH, FACP